Disease site number was not prognostic in a low-risk Hodgkin lymphoma combined modality trial: revisiting PHC HOD90
Blood Adv
.
2023 Nov 14;7(21):6665-6667.
doi: 10.1182/bloodadvances.2023010944.
Authors
Angela M Feraco
1
,
Yiwang Zhou
2
,
Ying Zheng
2
,
Lianna J Marks
3
,
Alison Friedmann
4
,
Howard J Weinstein
4
,
Michael P Link
3
,
Jamie E Flerlage
5
Affiliations
1
Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA.
2
Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, TN.
3
Stanford Children's Health, Stanford University, Stanford, CA.
4
Pediatric Hematology/Oncology, Massachusetts General Hospital for Children, Boston, MA.
5
Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN.
PMID:
37647596
PMCID:
PMC10637876
DOI:
10.1182/bloodadvances.2023010944
No abstract available
Publication types
Research Support, N.I.H., Extramural
MeSH terms
Hodgkin Disease* / diagnosis
Hodgkin Disease* / drug therapy
Humans
Lymphoma, Non-Hodgkin*
Prognosis
Grants and funding
P30 CA021765/CA/NCI NIH HHS/United States